DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Serevent Diskus (Salmeterol Xinafoate Inhalation Powder) - Published Studies

 
 



Published Studies Related to Serevent Diskus (Salmeterol Inhalation Powder)

Well-designed clinical trials related to Serevent Diskus (Salmeterol Inhalation Powder)

Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011.03]

Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. [2010.11.15]

Effect of addition of salmeterol versus doubling the dose of fluticasone propionate on specific airway resistance in children with asthma. [2010.09]

Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial. [2010.03]

Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterol/fluticasone propionate in asthma patients aged >or=16 years: post hoc analysis of a randomized, double-blind/open-label extension, parallel-group study. [2010]

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. [2010]

Add-on salmeterol compared to double dose fluticasone in pediatric asthma: a double-blind, randomized trial (VIAPAED). [2009.11]

Add-on salmeterol compared to double dose fluticasone in pediatric asthma: A double-blind, randomized trial (VIAPAED). [2009.10.12]

Childhood evaluation of salmeterol tolerance - A double-blind randomized controlled trial. [2009.08.27]

Fluticasone propionate/salmeterol and exercise-induced asthma in children with persistent asthma. [2009.05]

Efficacy and tolerability of salmeterol/fluticasone propionate versus montelukast in childhood asthma: A prospective, randomized, double-blind, double-dummy, parallel-group study. [2008.08]

Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. [2008.05]

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma. [2007.07.14]

Salmeterol improves pulmonary function in persons with tetraplegia. [2006.11]

Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol. [2006.07]

Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. [2006.02]

Minimal tolerance to the bronchoprotective effect of inhaled salmeterol/fluticasone combination on allergene challenge. [2006]

Efficacy and safety of salmeterol/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. [2005.07]

The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. [2005.04]

[Asthma control with the salmeterol-fluticasone-combination disc compared to standard treatment] [2005.03]

The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. [2005]

Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-acting beta2-agonists. [2004.10]

Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. [2004.05]

Eformoterol Turbohaler compared with salmeterol by dry powder inhaler in asthmatic children not controlled on inhaled corticosteroids. [2004.02]

Salmeterol/fluticasone propionate (50/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. [2004.01.24]

A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. [2004]

Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. [2004]

[A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination] [2003.11]

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. [2003.09]

Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. [2003.01]

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. [2002.10.15]

The effects of inhaled albuterol and salmeterol in 2- to 5-year-old asthmatic children as measured by impulse oscillometry. [2002.09]

Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD. [2002.06]

Step-down therapy with low-dose fluticasone-salmeterol combination or medium-dose hydrofluoroalkane 134a-beclomethasone alone. [2002.06]

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. [2002.05]

Acute protection against exercise-induced bronchoconstriction by formoterol, salmeterol and terbutaline. [2002.05]

Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. [2002.03]

Impact of inhaled salmeterol/fluticasone propionate combination product versus budesonide on the health-related quality of life of patients with asthma. [2002]

Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. [2001.09.01]

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. [2001.08]

Clinical equivalence of salmeterol/fluticasone propionate in combination (50/100 microg twice daily) when administered via a chlorofluorocarbon-free metered dose inhaler or dry powder inhaler to patients with mild-to-moderate asthma. [2001.02]

Salmeterol and fluticasone propionate given as a combination. Lack of systemic pharmacodynamic and pharmacokinetic interactions. [2001.01]

Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. [2001]

Salmeterol/fluticasone propionate (50/100 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in children with asthma. [2000.08]

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. [2000.06]

Comparison of powder and aerosol formulations of salmeterol in the treatment of asthma. [2000.03]

Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. [2000.02]

Salmeterol/fluticasone propionate (50/500 microg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. [1999.12]

Prevention of exercise-induced bronchospasm in pediatric asthma patients: A comparison of two salmeterol powder delivery devices. [1999.09]

Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation. [1999.08]

Prevention of exercise-induced bronchospasm in pediatric asthma patients: a comparison of salmeterol powder with albuterol. [1999.02]

Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers. [1999.01]

[Changes in specific airway resistance after powder inhalation of formoterol or salmeterol in moderate bronchial asthma] [1999.01]

A high dose of albuterol does not overcome bronchoprotective subsensitivity in asthmatic subjects receiving regular salmeterol or formoterol. [1999.01]

Comparison of salmeterol with beclomethasone in adult patients with mild persistent asthma who are already on low-dose inhaled steroids. [1999]

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. [1998.06]

Comparison of efficacy and ease of handling of salmeterol and terbutaline powder inhalers. [1998.03]

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. [1997.11]

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. [1996.08]

Efficacy and duration of salmeterol powder inhalation in protecting against exercise-induced bronchoconstriction. [1996.01]

Pilgrim's progress: the effect of salmeterol in older children with chronic severe asthma. [1995.07]

Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids. [1995.07]

Comparison of Diskus inhaler, a new multidose powder inhaler, with Diskhaler inhaler for the delivery of salmeterol to asthmatic patients. Canadian Study Group. [1995]

A single-dose comparison of inhaled albuterol and two formulations of salmeterol on airway reactivity in asthmatic subjects. [1991.09]

Well-designed clinical trials possibly related to Serevent Diskus (Salmeterol Inhalation Powder)

Maintaining asthma control in persistent asthma: comparison of three strategies in a 6-month double-blind randomised study. [2008.08]

Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. [2006.06.19]

Asthma inhalers and subsurface enamel demineralisation: an in situ pilot study. [2005.09]

Benefit from anti-inflammatory treatment during clinical remission of atopic asthma. [2005.06]

Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. [2005.06]

Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma. [1998.03]

Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. [1998.02]

Other research related to Serevent Diskus (Salmeterol Inhalation Powder)

Non-inferiority trial between two dry-powder inhalers containing fluticasone/salmeterol in asthmatic patients. [2013]

Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. [2012.01]

Comparative pulmonary function and pharmacokinetics of fluticasone propionate and salmeterol xinafoate delivered by two dry powder inhalers to patients with asthma. [2011.10]

Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. [2011.10]

Evaluation of fluticasone propionate and fluticasone propionate/salmeterol combination on exercise in pediatric and adolescent patients with asthma. [2011]

Long-term treatment with fluticasone propionate/salmeterol via Diskus improves asthma control versus fluticasone propionate alone. [2011]

Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary disease. [2010.10.21]

Combination Therapy Salmeterol/Fluticasone versus Doubling Dose of Fluticasone in Children with Asthma. [2010.07.09]

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. [2010.02]

Childhood evaluation of salmeterol tolerance--a double-blind randomized controlled trial. [2010]

Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. [2009.11.05]

Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. [2009.10.07]

Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. [2009.08]

Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. [2009.06.28]

Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation. [2009.03]

Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation. [2009.02.15]

Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 microg and fluticasone propionate 250 microg: implications for establishing bioequivalence of inhaled products. [2009.02]

Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals. [2009.02]

Darunavir: a review of its use in the management of HIV infection in adults. [2009]

Comparison of the clinical efficacy and safety of salmeterol/fluticasone propionate versus current care in the management of persistent asthma in Korea. [2008.12]

[Influence of changing inhalation device from separate diskus of salmeterol and fluticasone propionate to combination diskus in asthma patients] [2008.11]

Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down". [2008.10]

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. [2008.06]

Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment. [2008.06]

Efficacy and safety of fluticasone propionate/salmeterol 250/50mcg Diskus administered once daily. [2008.04]

Salmeterol/Fluticasone Propionate via Diskustrade mark Once Daily versus Fluticasone Propionate Twice Daily in Patients with Mild Asthma not Previously Receiving Maintenance Corticosteroids. [2008]

Initiation of maintenance therapy with salmeterol/fluticasone propionate combination therapy in moderate asthma: a comparison with fluticasone propionate. [2007.07]

Adhesion and redistribution of salmeterol xinafoate particles in sugar-based mixtures for inhalation. [2007.06.07]

Addition of transdermal or inhaled long-acting Beta2-agonists in adult asthmatic patients treated with inhaled corticosteroids: switchover study from tulobuterol patch to salmeterol dry powder inhaler. [2007.03]

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. [2007]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017